Evidence map›Paper›PMID 26634024›Full record

ReviewMethodist DeBakey cardiovascular journal

Endothelium-Derived Nitric Oxide as an Antiatherogenic Mechanism: Implications for Therapy.

Roman A Sukhovershin, Gautham Yepuri, Yohannes T Ghebremariam

Open access · diamondAbstract readReview
In one paragraph

Review in Methodist DeBakey cardiovascular journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Exercise and vascular function in sedentary lifestyles in humans.Pflugers Archiv : European journal of physiology · 2023
    Review
  6. Effects of sesame (Food science & nutrition · 2023
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Roles of eNOS in atherosclerosis treatment.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019
    Review
  14. Article
  15. Review
  16. Frontiers in pharmacology · 2019
    Article
  17. Article
  18. Article
  19. Article
  20. Vascular Aging: Implications for Cardiovascular Disease and Therapy.Translational medicine (Sunnyvale, Calif.) · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Roman A SukhovershinHouston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, Texas.
Gautham YepuriHouston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, Texas.
Yohannes T GhebremariamHouston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, Texas.
Methodist Hospital · USHouston Methodist · US

Funding

DDAH As a Novel Target in Pulmonary FibrosisK01HL118683 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI GHEBRE, YOHANNES T · 2013 to 2017
$682k
NHLBI NIH HHS K01 HL118683
6 · The paper itself

Abstract

Endothelium-derived nitric oxide (eNO) is a multifunctional signaling molecule critically involved in the maintenance of metabolic and cardiovascular homeostasis. In addition to its role as a potent endogenous vasodilator, eNO suppresses key processes in vascular lesion formation and opposes atherogenesis. This review discusses eNO as an antiatherogenic molecule and highlights factors that influence its bioavailability and therapeutic approaches to restore or enhance its levels.

Indexed as

Signal TransductionAnimalsAtherosclerosisCardiovascular AgentsEndothelium, VascularGene Expression Regulation, EnzymologicHumansNitric OxideNitric Oxide Synthase Type IIIPlaque, AtheroscleroticVasodilationCardiovascular AgentsNitric OxideNitric Oxide Synthase Type IIINOS3 protein, humanantiatherogenicasymmetric dimethylarginineatherosclerosisdimethylarginine dimethylaminohydrolaseendothelial nitric oxide synthaseendotheliumnitric oxidevascular dysfunction

Identifiers

PMID26634024
PMCPMC4666423
OpenAlexW2243333308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.